LLY
1,014.98
-0.96%↓
JNJ
240.9
+1.12%↑
ABBV
220.69
-0.72%↓
NVS
159.71
+1.01%↑
MRK
119.32
+1.9%↑
LLY
1,014.98
-0.96%↓
JNJ
240.9
+1.12%↑
ABBV
220.69
-0.72%↓
NVS
159.71
+1.01%↑
MRK
119.32
+1.9%↑
LLY
1,014.98
-0.96%↓
JNJ
240.9
+1.12%↑
ABBV
220.69
-0.72%↓
NVS
159.71
+1.01%↑
MRK
119.32
+1.9%↑
LLY
1,014.98
-0.96%↓
JNJ
240.9
+1.12%↑
ABBV
220.69
-0.72%↓
NVS
159.71
+1.01%↑
MRK
119.32
+1.9%↑
LLY
1,014.98
-0.96%↓
JNJ
240.9
+1.12%↑
ABBV
220.69
-0.72%↓
NVS
159.71
+1.01%↑
MRK
119.32
+1.9%↑
24h
Atual
Mín
Máximo
Recomendações | Comprar |
|---|---|
Previsão para 12 meses | +11.93% upside |
By Acuity
50%
50%
149 / 352 Ranking em Healthcare
O desempenho passado não é um indicador confiável de resultados futuros.
24 de out. de 2025, 13:04 UTC
Eli Lilly Agrees to Acquire Adverum Biotechnologies
DJ
Ler
9 de dez. de 2025, 13:32 UTC
Eli Lilly: Parties Expect to Consummate the Acquisition on Dec 9 >LLY
DJ
Ler
9 de dez. de 2025, 13:32 UTC
Lilly and Purchaser Accepted for Payment, and Will Promptly Pay, for All Shrs
DJ
Ler
9 de dez. de 2025, 13:29 UTC
Lilly and Adverum Announce Expiration and Completion of Adverum Tender Offer and Acquisition
DJ
Ler
24 de out. de 2025, 12:34 UTC
Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY
DJ
Ler
24 de out. de 2025, 12:34 UTC
Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY
DJ
Ler
24 de out. de 2025, 12:33 UTC
Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY
DJ
Ler
24 de out. de 2025, 12:30 UTC
Lilly To Acquire Adverum Biotechnologies >LLY ADVM
DJ
Ler
Variação de preço
By TipRanks
Previsão para 12 meses
Média 4.88 USD 11.93%
Máximo 5.5 USD
Mínimo 4 USD
Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Adverum Biotechnologies Inc - Dist nos últimos 3 meses.
By TipRanks
Comprar
5 ratings
2
Comprar
3
Manter
0
Vender
Com base em 5 analistas que deram avaliações de ações para Adverum Biotechnologies Inc - Dist nos últimos 3 meses.
By Acuity
Sentimento de Notícias
Neutral
Volatilidade
Abaixo da média
Volume de Notícias (RCV)
Abaixo da média
$